OncoMatch/Clinical Trials/NCT06529822
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Official title: Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Is NCT06529822 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments including Synthetic long peptide personalized cancer vaccine and Poly ICLC for muscle-invasive bladder carcinoma.
Treatment: Synthetic long peptide personalized cancer vaccine · Poly ICLC · Signatera or Altera testing — This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Gastric Cancer
Esophageal Carcinoma
Melanoma
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: CTDNA positive
ctDNA positive result as identified by Signatera
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: investigational agent
Exception: perioperative neoadjuvant chemotherapy and immunotherapy allowed
Receiving any other investigational agents, or planning to receive other investigational agents as part of neoadjuvant therapy. Patients who have received perioperative neoadjuvant chemotherapy and immunotherapy, including enfortumab vedotin plus pembrolizumab (EV+P), are allowed.
Cannot have received: investigational agent
Exception: perioperative neoadjuvant chemotherapy and immunotherapy allowed
Receiving any other investigational agents or planning to receive other investigational agents as part of neoadjuvant therapy. Patients who have received perioperative neoadjuvant chemotherapy and immunotherapy are allowed.
Cannot have received: investigational agent
Receiving any other investigational agents or planning to receive other investigational agents in the neoadjuvant or adjuvant setting.
Lab requirements
Blood counts
wbc ≥ 1.5 k/cumm; absolute neutrophil count ≥ 1.0 k/cumm; platelets ≥ 50 k/cumm; hemoglobin ≥ 8.0 g/dl
Kidney function
creatinine clearance > 30 ml/min by cockcroft-gault
Liver function
total bilirubin ≤ 1.5 x iuln; ast(sgot)/alt(sgpt) ≤ 3.0 x iuln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- AdventHealth · Orlando, Florida
- Washington University School of Medicine · St Louis, Missouri
- Ohio State University · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06529822 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent, investigational agent, investigational agent disqualifies patients from enrollment.
Does this trial require CTDNA?
Yes, CTDNA positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages